Journal article
N-acetyl cysteine add-on treatment for bipolar II disorder: A subgroup analysis of a randomized placebo-controlled trial
PV Magalhães, OM Dean, AI Bush, DL Copolov, GS Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk
Journal of Affective Disorders | Published : 2011
Abstract
Background: The evidence base for the pharmacological treatment of bipolar II disorder is limited. In bipolar disorder, there is evidence for glutathione depletion and increased oxidative stress, as well as dysregulation of glutamate; N-acetyl cysteine (NAC) has effects on both of these systems. Add-on NAC has been shown to have a significant benefit on depressive symptoms in a randomized placebo-controlled trial. In this report, we explore the effects of this compound in a subset of patients with bipolar II disorder from that trial. Methods: Individuals were randomized to NAC or placebo in addition to treatment as usual, in a double-blind fashion. Mood and functional outcomes were assessed ..
View full abstractGrants
Funding Acknowledgements
[ "This trial was supported by a grant from the Stanley Medical Research Institute, as well as the Mental Health Research Institute of Victoria.", "Dr. Magalhaes is supported by a split doctoral scholarship from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil.", "Prof. Malhi has served on a number of international and national pharmaceutical advisory boards, received funding for research and has been in receipt of honoraria for talks at sponsored meetings worldwide involving the following companies: Astra Zeneca, Eli Lilly, Janssen-Cilag, Lundbeck, Organon, Pfizer, Ranbaxy, Servier and Wyeth.", "Prof. Berk has received research support from: Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma, Servier. He has been a speaker for Speaker: Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay, Wyeth. He has been a consultant for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Servier." ]